Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
The Lung Institute of Western Australia &CAARR Postgraduate Research For the six million Australians who struggle to take a breath, LIWA offers support and hope for a healthier future. Why Research Lung Disease 6 Million Australians struggle to breathe. 60 x Almost one in three Australians Melbourne Cricket Ground Why lung disease? A major problem for Australia; • Asthma – Australia &NZ highest in world • Emphysema – 4th most common cause of death • Lung cancer – Most lethal of all cancers • Cystic fibrosis – most common genetic disease • Pneumonia – a major problem for the elderly & & infection indigenous people • Bronchiectasis – an emerging epidemic in Australia • Mesothelioma – asbestos & WA • Pul. Hypertension – poorly recognised Our Research Philosophy Address the breadth of lung disease using the best research tools available • Bridge lab to clinic • Encourage a multidisciplinary approach • Encourage networking & collaboration • Ensure mutual recognition of the merits of both Basic and Clinical science LIWA’s Aims • Support high quality research • Support young scientists • Educational & scientific resource for the community • Improve well-being of patients • Be an advocacy group for better lung health Cadets, Thomas and Sarah LIWA’s Research Units Biological Sciences Research Clinical Sciences Research World Class Researchers •Tissue Repair, Inflammation & Cancer •Molecular Genetics •Pleural Disease •Stem Cell •Clinical Trials Unit •Pul. Vascular Disease •Physiotherapy •Cardiothoracic Surgery •Cystic Fibrosis /Bronchiectasis LIWA’s Research Units Biological Sciences Research •Tissue Repair, Inflammation & Cancer •Head – Steve Mutsaers •Research Activities • Micro RNA and mesothelioma • Sonic Hedgehog signalling in mesothelioma & lung cancer • STAT signalling in pulmonary fibrosis • Stem cells in mesothelial tissue repair • Role of kinins in tumour angiogenesis Funding •NH&MRC •Dust Diseases Board of NSW LIWA’s Research Units Biological Sciences Research •Molecular Genetics Unit •Head – Phil Thompson •Research Activities • Antisense therapies for Asthma • Pharmacogenetics of Asthma medications • Gene regulation & role of splice variants as regulators of inflammatory pathways • Candidate gene polymorphisms • GWAS for asthma in national/international consortia Funding NH&MRC CRC for Asthma and Airways LIWA’s Research Units Biological Sciences Research •Pleural Disease Unit •Head – Gary Lee •Research Activities • Development of biomarkers of mesothelioma • Mechanisms of pleural effusion development • Better management of Pleural effusion •Mechanisms underlying pleural infection Funding Welcome Trust, MRC UK Raine; LIWA; State Government LIWA’s Research Units Biological Sciences Research •Stem Cell Unit •Head – Yuben Moodley •Research Activities • Use of mesenchymal stem cells in COPD • Animal studies on mesenchymal stem cells for lung repair •Development of a tracheal explant model for assessing injury repair pathways Funding RPH UWA LIWA’s Research Units Clinical Sciences Research •Clinical Trials Unit Largest respiratory trials unit in Australia •Pul. Vascular Disease & Transplantation Recognised internationally for pioneering work on early detection of Pul Hypertenison •Physiotherapy Lead group in developing assessments of breathlessness •Cystic Fibrosis /Bronchiectasis New unit looking at inflammatory mediators in these diseases and new treatments •Cardiothoracic Surgery Prevention of ischaemic injury during surgery Funding LIWA derives its income from diverse sources. INCOME 1% 2% 0% 23% 40% 11% EXPENSES 23% SALARIES RESEARCH CONSUMABLES INTERNATIONAL GRANTS NATIONAL GRANTS LOCAL GRANTS CLINICAL TRIALS DONATIONS MEMBERSHIPS CONTRACTS ADMINISTRATION 11% 18% Over 70% of our expenditure is on research. 71% LIWA RESEARCH • Is multifaceted, bridges lab to clinic • Has national and international collaborations • Welcomes partnering in research either at the laboratory or patient level